University of Hasselt-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2023

  1. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  2. Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence

    Multiple Sclerosis and Related Disorders, Vol. 69

  3. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

2022

  1. Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in

    Frontiers in Immunology, Vol. 13

  2. Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180

    Computer methods and programs in biomedicine

  3. Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial

    European Journal of Neurology, Vol. 29, Núm. 3, pp. 790-801

  4. Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide

    Frontiers in Immunology, Vol. 13

2021

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, Vol. 208

2020

  1. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, Vol. 143, Núm. 9, pp. 2742-2756

2019

  1. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings

    Frontiers in Neurology, Vol. 10

2018

  1. Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

    Therapeutic Advances in Neurological Disorders, Vol. 11

2015

  1. Can we offer more to patients with multiple sclerosis?

    European Neurological Review, Vol. 10, Núm. 2, pp. 139-147